WJNS  Vol.4 No.2 , May 2014
In Vivo 9.4T MRI and 1H MRS for Evaluation of Brain Structural and Metabolic Changes in the Ts65Dn Mouse Model for Down Syndrome
ABSTRACT

In the present study we investigated structural and metabolic modifications of the brain in the Ts65Dn mouse model of Down syndrome(DS)using both in vivo magnetic resonance imaging(MRI)and proton magnetic resonance spectroscopy(MRS). MRI was performed for further texture analysis and changes in texture parameters, including mean grey levels, contrast and homogeneity, and they were found in Ts65Dn compared to diploid littermates (2n). These phenotypic changes were different in the hippocampus and cerebellum, since in Ts65Dn mean grey levels increased in the cerebellum and decreased in the hippocampus. In addition, proton NMR spectra revealed differences in metabolite ratios. Levels of N-acetylaspartate(NAA)and glutamate(Glu), were lower compared to total creatine levels (CX), in the Ts65Dn brain. However, the most striking finding was an increase in the concentration of myo-inositol(Ins)and choline(Cho)in the hippocampus, whereas the Ins concentration was reduced in the cerebellum. Overall, these data illustrate that MRI and MRS are valuable assesment tools sufficiently sensitive to detect associated changes in different brain areas, thus providing new insight into the causative role of dosage-sensitive genes in the Ts65Dn DS mouse model.


Cite this paper
Même, S. , Joudiou, N. , Yousfi, N. , Szeremeta, F. , Lopes-Pereira, P. , Beloeil, J. , Herault, Y. and Même, W. (2014) In Vivo 9.4T MRI and 1H MRS for Evaluation of Brain Structural and Metabolic Changes in the Ts65Dn Mouse Model for Down Syndrome. World Journal of Neuroscience, 4, 152-163. doi: 10.4236/wjns.2014.42018.
References
[1]   Crome, L. and Erdohazi, M. (1966) Main Pathological Findings in Hydrocephalic Children Treated by VentriculoAtrial Shunt. Archives of Disease in Childhood, 41, 179-182. http://dx.doi.org/10.1136/adc.41.216.179

[2]   Jernigan, T.L., et al., (1993) Cerebral Morphologic Distinctions between Williams and Down Syndromes. Archives of Neurology, 50, 186-191. http://dx.doi.org/10.1001/archneur.1993.00540020062019

[3]   Coyle, J.T., Oster-Granite, M.L., and Gearhart, J.D. (1986) The Neurobiologic Consequences of Down Syndrome. Brain Research Bulletin, 16, 773-787. http://dx.doi.org/10.1016/0361-9230(86)90074-2

[4]   Griffin, W.S., et al., (1989) Brain Interleukin 1 and S-100 Immunoreactivity Are Elevated in Down Syndrome and Alzheimer Disease. Proceedings of the National Academy of Sciences of the United States of America, 86, 7611-7615.
http://dx.doi.org/10.1073/pnas.86.19.7611

[5]   Rumble, B., et al., (1989) Amyloid A4 Protein and Its Precursor in Down Syndrome and Alzheimer’s Disease. The New England Journal of Medicine, 320, 1446-1452. http://dx.doi.org/10.1056/NEJM198906013202203

[6]   Sabbagh, M.N., et al., (2011) Positron Emission Tomography and Neuropathologic Estimates of Fibrillar AmyloidBeta in a Patient with Down Syndrome and Alzheimer Disease. Archives of Neurology, 68, 1461-1466.
http://dx.doi.org/10.1001/archneurol.2011.535

[7]   Braudeau, J., et al., (2011) Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model. Advances in Pharmacological Sciences, 2011, Article ID: 153218.

[8]   Das, I. and Reeves, R.H. (2011) The Use of Mouse Models to Understand and Improve Cognitive Deficits in Down Syndrome. Disease Models & Mechanisms, 4, 596-606. http://dx.doi.org/10.1242/dmm.007716

[9]   De la Torre, R., et al., (2013) Epigallocatechin-3-gallate, a DYRK1A Inhibitor, Rescues Cognitive Deficits in Down Syndrome Mouse Models and in Humans. Molecular Nutrition & Food Research, 58, 278-288.

[10]   Jiang, J., et al., (2013) Translating Dosage Compensation to Trisomy 21. Nature, 500, 296-300.
http://dx.doi.org/10.1038/nature12394

[11]   Herault, Y., et al., (2012) The in Vivo Down Syndrome Genomic Library in Mouse. Progress in Brain Research, 197, 169-197. http://dx.doi.org/10.1016/B978-0-444-54299-1.00009-1

[12]   Rueda, N., Florez, J. and Martinez-Cue, C. (2012) Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities. Neural Plasticity, 2012, Article ID: 584071.

[13]   Davisson, M.T., Schmidt, C. and Akeson, E.C. (1990) Segmental Trisomy of Murine Chromosome 16: A New Model System for Studying Down Syndrome. Progress in Clinical and Biological Research, 360, 263-280.

[14]   Davisson, M.T., et al., (1993) Segmental Trisomy as a Mouse Model for Down Syndrome. Progress in Clinical and Biological Research, 384, 117-133.

[15]   Reeves, R.H., et al., (1995) A Mouse Model for Down Syndrome Exhibits Learning and Behaviour Deficits. Nature Genetics, 11, 177-184. http://dx.doi.org/10.1038/ng1095-177

[16]   Li, Z., et al. (2007) Duplication of the Entire 22.9 Mb Human Chromosome 21 Syntenic Region on Mouse Chromosome 16 Causes Cardiovascular and Gastrointestinal Abnormalities. Human Molecular Genetics, 16, 1359-1366.
http://dx.doi.org/10.1093/hmg/ddm086

[17]   O’Doherty, A., et al. (2005) An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes. Science, 309, 2033-2037. http://dx.doi.org/10.1126/science.1114535

[18]   Olson, L.E., et al. (2007) Trisomy for the Down Syndrome “Critical Region” Is Necessary but Not Sufficient for Brain Phenotypes of Trisomic Mice. Human Molecular Genetics, 16, 774-782. http://dx.doi.org/10.1093/hmg/ddm022

[19]   Pereira, P.L., et al. (2009) A New Mouse Model for the Trisomy of the Abcg1-U2af1 Region Reveals the Complexity of the Combinatorial Genetic Code of Down Syndrome. Human Molecular Genetics, 18, 4756-4769.
http://dx.doi.org/10.1093/hmg/ddp438

[20]   Yu, T., et al. (2010) A Mouse Model of Down Syndrome Trisomic for All Human Chromosome 21 Syntenic Regions. Human Molecular Genetics, 19, 2780-2791. http://dx.doi.org/10.1093/hmg/ddq179

[21]   Holtzman, D.M., et al. (1996) Developmental Abnormalities and Age-Related Neurodegeneration in a Mouse Model of Down Syndrome. Proceedings of the National Academy of Sciences of the United States of America, 93, 13333-13338.
http://dx.doi.org/10.1073/pnas.93.23.13333

[22]   Dierssen, M., Herault, Y. and Estivill, X. (2009) Aneuploidy: From a Physiological Mechanism of Variance to Down Syndrome. Physiological Reviews, 89, 887-920. http://dx.doi.org/10.1152/physrev.00032.2007

[23]   Aldridge, K., et al. (2007) Differential Effects of Trisomy on Brain Shape and Volume in Related Aneuploid Mouse Models. American Journal of Medical Genetics Part A, 143A, 1060-1070. http://dx.doi.org/10.1002/ajmg.a.31721

[24]   Belichenko, P.V., et al. (2004) Synaptic Structural Abnormalities in the Ts65Dn Mouse Model of Down Syndrome. Journal of Comparative Neurology, 480, 281-298. http://dx.doi.org/10.1002/cne.20337

[25]   Best, T.K., Siarey, R.J. and Galdzicki, Z. (2007) Ts65Dn, a Mouse Model of Down Syndrome, Exhibits Increased GABAB-Induced Potassium Current. Journal of Neurophysiology, 97, 892-900.
http://dx.doi.org/10.1152/jn.00626.2006

[26]   Contestabile, A., et al. (2007) Cell Cycle Alteration and Decreased Cell Proliferation in the Hippocampal Dentate Gyrus and in the Neocortical Germinal Matrix of Fetuses with Down Syndrome and in Ts65Dn Mice. Hippocampus, 17, 665-678. http://dx.doi.org/10.1002/hipo.20308

[27]   Dierssen, M., et al. (2003) Alterations of Neocortical Pyramidal Cell Phenotype in the Ts65Dn Mouse Model of Down Syndrome: Effects of Environmental Enrichment. Cerebral Cortex, 13, 758-764.
http://dx.doi.org/10.1093/cercor/13.7.758

[28]   Escorihuela, R.M., et al. (1995) A Behavioral Assessment of Ts65Dn Mice: A Putative Down Syndrome Model. Neuroscience Letters, 199, 143-146. http://dx.doi.org/10.1016/0304-3940(95)12052-6

[29]   Escorihuela, R.M., et al. (1998) Impaired Shortand Long-Term Memory in Ts65Dn Mice, a Model for Down Syndrome. Neuroscience Letters, 247, 171-174. http://dx.doi.org/10.1016/S0304-3940(98)00317-6

[30]   Hanson, J.E., et al. (2007) The Functional Nature of Synaptic Circuitry Is Altered in Area CA3 of the Hippocampus in a Mouse Model of Down’s Syndrome. The Journal of Physiology, 579, 53-67.
http://dx.doi.org/10.1113/jphysiol.2006.114868

[31]   Insausti, A.M., et al. (1998) Hippocampal Volume and Neuronal Number in Ts65Dn Mice: A Murine Model of Down Syndrome. Neuroscience Letters, 253, 175-178. http://dx.doi.org/10.1016/S0304-3940(98)00641-7

[32]   Kurt, M.A., et al. (2000) Synaptic Deficit in the Temporal Cortex of Partial Trisomy 16 (Ts65Dn) Mice. Brain Research, 858, 191-197. http://dx.doi.org/10.1016/S0006-8993(00)01984-3

[33]   Siarey, R.J., et al. (2006) Altered Signaling Pathways Underlying Abnormal Hippocampal Synaptic Plasticity in the Ts65Dn Mouse Model of Down Syndrome. Journal of Neurochemistry, 98, 1266-1277.
http://dx.doi.org/10.1111/j.1471-4159.2006.03971.x

[34]   Seo, H. and Isacson, O. (2005) Abnormal APP, Cholinergic and Cognitive Function in Ts65Dn Down’s Model Mice. Experimental Neurology, 193, 469-480. http://dx.doi.org/10.1016/j.expneurol.2004.11.017

[35]   Ruparelia, A., Pearn, M.L. and Mobley, W.C. (2012) Cognitive and Pharmacological Insights from the Ts65Dn Mouse Model of Down Syndrome. Current Opinion in Neurobiology, 22, 880-886.
http://dx.doi.org/10.1016/j.conb.2012.05.002

[36]   Denic, A., et al. (2011) MRI in Rodent Models of Brain Disorders. Neurotherapeutics, 8, 3-18.
http://dx.doi.org/10.1007/s13311-010-0002-4

[37]   Meme, S., et al. (2009) MRI Characterization of Structural Mouse Brain Changes in Response to Chronic Exposure to the Glufosinate Ammonium Herbicide. Toxicological Sciences, 111, 321-330. http://dx.doi.org/10.1093/toxsci/kfp174

[38]   Herlidou, S., et al. (1999) Comparison of Automated and Visual Texture Analysis in MRI: Characterization of Normal and Diseased Skeletal Muscle. Magnetic Resonance Imaging, 17, 1393-1397.
http://dx.doi.org/10.1016/S0730-725X(99)00066-1

[39]   Julesz, B., et al. (1973) Inability of Humans to Discriminate between Visual Textures That Agree in Second-Order Statistics-Revisited. Perception, 2, 391-405. http://dx.doi.org/10.1068/p020391

[40]   Calas, A.G., et al. (2008) Chronic Exposure to Glufosinate-Ammonium Induces Spatial Memory Impairments, Hippocampal MRI Modifications and Glutamine Synthetase Activation in Mice. Neurotoxicology, 29, 740-747.
http://dx.doi.org/10.1016/j.neuro.2008.04.020

[41]   Conners, R.W. and Harlow, C.A. (1980) A Theoretical Comparison of Texture Algorithms. IEEE Transactions on Pattern Analysis and Machine Intelligence, 2, 204-222. http://dx.doi.org/10.1109/TPAMI.1980.4767008

[42]   Jirak, D., et al. (2002) Texture Analysis of Human Liver. Journal of Magnetic Resonance Imaging, 15, 68-74.
http://dx.doi.org/10.1002/jmri.10042

[43]   Herlidou, S., et al. (2004) Influence of Age and Osteoporosis on Calcaneus Trabecular Bone Structure: A Preliminary in Vivo MRI Study by Quantitative Texture Analysis. Magnetic Resonance Imaging, 22, 237-343.
http://dx.doi.org/10.1016/j.mri.2003.07.007

[44]   Herlidou-Meme, S., et al. (2003) MRI Texture Analysis on Texture Test Objects, Normal Brain and Intracranial Tumors. Magnetic Resonance Imaging, 21, 989-993. http://dx.doi.org/10.1016/S0730-725X(03)00212-1

[45]   Baxter, L.L., et al. (2000) Discovery and Genetic Localization of Down Syndrome Cerebellar Phenotypes Using the Ts65Dn Mouse. Human Molecular Genetics, 9, 195-202. http://dx.doi.org/10.1093/hmg/9.2.195

[46]   Sebrie, C., et al. (2008) Increased Dosage of DYRK1A and Brain Volumetric Alterations in a YAC Model of Partial Trisomy 21. The Anatomical Record, 291, 254-262. http://dx.doi.org/10.1002/ar.20640

[47]   Chen, Y., et al. (2009) In Vivo MRI Identifies Cholinergic Circuitry Deficits in a Down Syndrome Model. Neurobiology of Aging, 30, 1453-1465. http://dx.doi.org/10.1016/j.neurobiolaging.2007.11.026

[48]   Filippi, C.G., et al. (2002) Developmental Delay in Children: Assessment with Proton MR Spectroscopy. American Journal of Neuroradiology, 23, 882-888.

[49]   Yao, F.S., Caserta, M.T. and Wyrwicz, A.M. (2000) In Vitro 1H and 31P NMR Spectroscopic Evidence of Multiple Aberrant Biochemical Pathways in Murine Trisomy 16 Brain Development. International Journal of Developmental Neuroscience, 18, 833-841. http://dx.doi.org/10.1016/S0736-5748(00)00043-5

[50]   Huang, W., et al. (2000) Brain Myo-Inositol Level Is Elevated in Ts65Dn Mouse and Reduced after Lithium Treatment. NeuroReport, 11, 445-448. http://dx.doi.org/10.1097/00001756-200002280-00004

[51]   Shetty, H.U., et al. (1996) Brain Accumulation of Myo-Inositol in the Trisomy 16 Mouse, an Animal Model of Down’s Syndrome. Biochemical Journal, 313, 31-33.

[52]   Morris, R.G., et al. (1982) Place Navigation Impaired in Rats with Hippocampal Lesions. Nature, 297, 681-683.
http://dx.doi.org/10.1038/297681a0

[53]   Fernandez, F. and Garner, C.C. (2008) Episodic-Like Memory in Ts65Dn, a Mouse Model of Down Syndrome. Behavioural Brain Research, 188, 233-237. http://dx.doi.org/10.1016/j.bbr.2007.09.015

[54]   Demas, G.E., et al. (1996) Spatial Memory Deficits in Segmental Trisomic Ts65Dn Mice. Behavioural Brain Research, 82, 85-92. http://dx.doi.org/10.1016/S0166-4328(97)81111-4

[55]   Kleschevnikov, A.M., et al. (2004) Hippocampal Long-Term Potentiation Suppressed by Increased Inhibition in the Ts65Dn Mouse, a Genetic Model of Down Syndrome. The Journal of Neuroscience, 24, 8153-8160.
http://dx.doi.org/10.1523/JNEUROSCI.1766-04.2004

[56]   Galdzicki, Z. and Siarey, R.J. (2003) Understanding Mental Retardation in Down’s Syndrome Using Trisomy 16 Mouse Models. Genes, Brain and Behavior, 2, 167-178. http://dx.doi.org/10.1034/j.1601-183X.2003.00024.x

[57]   Kurt, M.A., et al. (2004) Deficits of Neuronal Density in CA1 and Synaptic Density in the Dentate Gyrus, CA3 and CA1, in a Mouse Model of Down Syndrome. Brain Research, 1022, 101-109.
http://dx.doi.org/10.1016/j.brainres.2004.06.075

[58]   Gotti, S., Caricati, E. and Panzica, G. (2011) Alterations of Brain Circuits in Down Syndrome Murine Models. Journal of Chemical Neuroanatomy, 42, 317-326. http://dx.doi.org/10.1016/j.jchemneu.2011.09.002

[59]   Lorenzi, H.A. and Reeves, R.H. (2006) Hippocampal Hypocellularity in the Ts65Dn Mouse Originates Early in Development. Brain Research, 1104, 153-159. http://dx.doi.org/10.1016/j.brainres.2006.05.022

[60]   Popov, V.I., et al. (2011) Three-Dimensional Synaptic Ultrastructure in the Dentate Gyrus and Hippocampal Area CA3 in the Ts65Dn Mouse Model of Down Syndrome. Journal of Comparative Neurology, 519, 1338-1354.
http://dx.doi.org/10.1002/cne.22573

[61]   Dickson, P.E., et al. (2010) Behavioral Flexibility in a Mouse Model of Developmental Cerebellar Purkinje Cell Loss. Neurobiology of Learning and Memory, 94, 220-228. http://dx.doi.org/10.1016/j.nlm.2010.05.010

[62]   Contestabile, A., et al. (2009) Cell Cycle Elongation Impairs Proliferation of Cerebellar Granule Cell Precursors in the Ts65Dn Mouse, an Animal Model for Down Syndrome. Brain Pathology, 19, 224-237.
http://dx.doi.org/10.1111/j.1750-3639.2008.00168.x

[63]   Olson, L.E., et al. (2004) Down Syndrome Mouse Models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn Exhibit Variable Severity of Cerebellar Phenotypes. Developmental Dynamics, 230, 581-589. http://dx.doi.org/10.1002/dvdy.20079

[64]   Marjanska, M., et al. (2005) Monitoring Disease Progression in Transgenic Mouse Models of Alzheimer’s Disease with Proton Magnetic Resonance Spectroscopy. Proceedings of the National Academy of Sciences of the United States of America, 102, 11906-11910. http://dx.doi.org/10.1073/pnas.0505513102

[65]   Miyasaka, N., Takahashi, K. and Hetherington, H.P. (2006) 1H NMR Spectroscopic Imaging of the Mouse Brain at 9.4T. Journal of Magnetic Resonance Imaging, 24, 908-913. http://dx.doi.org/10.1002/jmri.20709

[66]   Hsu, Y.Y., et al. (2001) Lateralization and Prognostic Value of Proton Magnetic Resonance Spectroscopy in Patients with Intractable Temporal Lobe Epilepsy. Chang Gung Medical Journal, 24, 768-778.

[67]   Jessen, F., et al. (2000) Proton MR Spectroscopy Detects a Relative Decrease of N-Acetylaspartate in the Medial Temporal Lobe of Patients with AD. Neurology, 55, 684-688. http://dx.doi.org/10.1212/WNL.55.5.684

[68]   Bambrick, L.L., Yarowsky, P.J. and Krueger, B.K. (2003) Altered Astrocyte Calcium Homeostasis and Proliferation in the Ts65Dn Mouse, a Model of Down Syndrome. Journal of Neuroscience Research, 73, 89-94.
http://dx.doi.org/10.1002/jnr.10630

[69]   Brand, A., Richter-Landsberg, C. and Leibfritz, D. (1993) Multinuclear NMR Studies on the Energy Metabolism of Glial and Neuronal Cells. Developmental Neuroscience, 15, 289-298. http://dx.doi.org/10.1159/000111347

[70]   Ceuterick, C., et al. (1998) Astroglial Tangles in the Hippocampus of Two Patients with Down Syndrome and Alzheimer Neuropathology. Ultrastructural Pathology, 22, 161-163. http://dx.doi.org/10.3109/01913129809032272

[71]   Jorgensen, O.S., Brooksbank, B.W. and Balazs, R. (1990) Neuronal Plasticity and Astrocytic Reaction in Down Syndrome and Alzheimer Disease. Journal of the Neurological Sciences, 98, 63-79.
http://dx.doi.org/10.1016/0022-510X(90)90182-M

[72]   Murphy Jr., G.M., et al. (1992) Astrocytic Gliosis in the Amygdala in Down’s Syndrome and Alzheimer’s Disease. Progress in Brain Research, 94, 475-483. http://dx.doi.org/10.1016/S0079-6123(08)61774-4

[73]   Belichenko, P.V., et al. (2007) Synaptic and Cognitive Abnormalities in Mouse Models of Down Syndrome: Exploring Genotype-Phenotype Relationships. Journal of Comparative Neurology, 504, 329-345.
http://dx.doi.org/10.1002/cne.21433

[74]   Belichenko, N.P., et al. (2009) The “Down Syndrome Critical Region” Is Sufficient in the Mouse Model to Confer Behavioral, Neurophysiological, and Synaptic Phenotypes Characteristic of Down Syndrome. The Journal of Neuroscience, 29, 5938-5948. http://dx.doi.org/10.1523/JNEUROSCI.1547-09.2009

[75]   Kleschevnikov, A.M., et al. (2012) Increased Efficiency of the GABAA and GABAB Receptor-Mediated Neurotransmission in the Ts65Dn Mouse Model of Down Syndrome. Neurobiology of Disease, 45, 683-691.
http://dx.doi.org/10.1016/j.nbd.2011.10.009

[76]   Dierssen, M., et al. (1997) Alterations of Central Noradrenergic Transmission in Ts65Dn Mouse, a Model for Down Syndrome. Brain Research, 749, 238-244. http://dx.doi.org/10.1016/S0006-8993(96)01173-0

[77]   Dierssen, M., et al. (1996) Impaired Cyclic AMP Production in the Hippocampus of a Down Syndrome Murine Model. Developmental Brain Research, 95, 122-124. http://dx.doi.org/10.1016/0165-3806(96)00071-5

[78]   Duchon, A., et al. (2011) The Telomeric Part of the Human Chromosome 21 from Cstb to Prmt2 Is Not Necessary for the Locomotor and Short-Term Memory Deficits Observed in the Tc1 Mouse Model of Down Syndrome. Behavioural Brain Research, 217, 271-281. http://dx.doi.org/10.1016/j.bbr.2010.10.023

[79]   Gruetter, R. (1993) Automatic, Localized in Vivo Adjustment of All Firstand Second-Order Shim Coils. Magnetic Resonance in Medicine, 29, 804-811. http://dx.doi.org/10.1002/mrm.1910290613

[80]   Tkac, I., et al. (1999) In Vivo 1H NMR Spectroscopy of Rat Brain at 1 ms Echo Time. Magnetic Resonance in Medicine, 41, 649-656. http://dx.doi.org/10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G

[81]   Vanhamme, L., van den Boogaart, A. and Van Huffel, S. (1997) Improved Method for Accurate and Efficient Quantification of MRS Data with Use of Prior Knowledge. Journal of Magnetic Resonance, 129, 35-43.
http://dx.doi.org/10.1006/jmre.1997.1244

[82]   van Eijsden, P., et al. (2010) In Vivo Neurochemical Profiling of Rat Brain by 1H-[13C] NMR Spectroscopy: Cerebral Energetics and Glutamatergic/GABAergic Neurotransmission. Journal of Neurochemistry, 112, 24-33.
http://dx.doi.org/10.1111/j.1471-4159.2009.06428.x

[83]   Xin, L., et al. (2010) 1H-[13C] NMR Spectroscopy of the Rat Brain during Infusion of [2-13C] Acetate at 14.1 T. Magnetic Resonance in Medicine, 64, 334-340.

 
 
Top